Literature DB >> 28846578

The lung rescue unit-Does a dedicated intensive care unit for venovenous extracorporeal membrane oxygenation improve survival to discharge?

Jay Menaker1, Katelyn Dolly, Raymond Rector, Joseph Kufera, Eugenia E Lee, Ali Tabatabai, Ronald P Rabinowitz, Zachary N Kon, Pablo Sanchez, Si Pham, Daniel L Herr, James V O'Connor, Deborah M Stein, Thomas M Scalea.   

Abstract

BACKGROUND: The use of venovenous extra corporeal membrane oxygenation (VV ECMO) for acute respiratory failure (ARF)/acute respiratory (ARDS) has increased since 2009. Specialized units for patients requiring VV ECMO are not standard and patients are often cohorted with other critically ill patients. The purpose of this study was to report the outcome of adult patients admitted in 2015 to the lung rescue unit, which, to our knowledge, is the first intensive care unit in the United States that has been specifically created to provide care for patients requiring VV ECMO.
METHODS: Data were collected on all patients admitted to the lung rescue unit on VV ECMO between January 1, 2015, and December 31, 2015. Demographics, medical history, pre-ECMO data, indication for VV ECMO as well as duration of ECMO and survival to decannulation and discharge were recorded. Means (± standard deviation) and medians (interquartile range [IQR]) were reported when appropriate.
RESULTS: Forty-nine patients were enrolled. Median age was 48 years (IQR, 32-57). Median PaO2/FIO2 ratio before cannulation was 66 (IQR, 53-86). Median ventilator days before cannulation was 2 (IQR, 1-4). Median time on VV ECMO for all patients was 311 hours (IQR, 203-461). Thirty-eight (78%) patients were successfully decannulated with 35 (71%) patients surviving to hospital discharge.
CONCLUSION: The use of VV ECMO for ARF/ARDS is increasing. We have demonstrated that a dedicated multidisciplinary intensive care unit for the purpose of providing standardized care with specialized trained providers can improve survival to discharge for patients that require VV ECMO for ARF/ARDS. LEVEL OF EVIDENCE: Therapeutic, level V.

Entities:  

Mesh:

Year:  2017        PMID: 28846578     DOI: 10.1097/TA.0000000000001524

Source DB:  PubMed          Journal:  J Trauma Acute Care Surg        ISSN: 2163-0755            Impact factor:   3.313


  9 in total

1.  The use of VV-ECMO in patients with drug dependencies.

Authors:  George Stoyle; Peter Fawcett; Ignacio Malagon
Journal:  J Artif Organs       Date:  2018-02-20       Impact factor: 1.731

2.  Similarities in extracorporeal membrane oxygenation management across intensive care unit types in the United States: An analysis of the Extracorporeal Life Support Organization Registry.

Authors:  Clark G Owyang; Claire Donnat; Daniel Brodie; Hayley B Gershengorn; May Hua; Nida Qadir; Joseph E Tonna
Journal:  Artif Organs       Date:  2022-02-11       Impact factor: 2.663

3.  ECMO-assisted resection of huge thoracic mass.

Authors:  Alireza Jahangirifard; Zargham Hossein Ahmadi; Abolghasem Daneshvar Kakhaki; Behrooz Farzanegan; Kambiz Sheikhy
Journal:  J Cardiovasc Thorac Res       Date:  2018-05-21

4.  Veno-Venous Extracorporeal Membrane Oxygenation (VV ECMO) for Acute Respiratory Failure Following Injury: Outcomes in a High-Volume Adult Trauma Center with a Dedicated Unit for VV ECMO.

Authors:  Jay Menaker; Ronald B Tesoriero; Ali Tabatabai; Ronald P Rabinowitz; Christopher Cornachione; Terence Lonergan; Katelyn Dolly; Raymond Rector; James V O'Connor; Deborah M Stein; Thomas M Scalea
Journal:  World J Surg       Date:  2018-08       Impact factor: 3.352

5.  Reserved Bed Program Reduces Neurosciences Intensive Care Unit Capacity Strain: An Implementation Study.

Authors:  Christopher D Shank; Nicholas J Erickson; David W Miller; Brittany F Lindsey; Beverly C Walters
Journal:  Neurosurgery       Date:  2020-01-01       Impact factor: 4.654

6.  A Dedicated Veno-Venous Extracorporeal Membrane Oxygenation Unit during a Respiratory Pandemic: Lessons Learned from COVID-19 Part I: System Planning and Care Teams.

Authors:  Sagar Dave; Aakash Shah; Samuel Galvagno; Kristen George; Ashley R Menne; Daniel J Haase; Brian McCormick; Raymond Rector; Siamak Dahi; Ronson J Madathil; Kristopher B Deatrick; Mehrdad Ghoreishi; James S Gammie; David J Kaczorowski; Thomas M Scalea; Jay Menaker; Daniel Herr; Eric Krause; Ali Tabatabai
Journal:  Membranes (Basel)       Date:  2021-04-02

7.  Body mass index does not impact survival in COVID-19 patients requiring veno-venous extracorporeal membrane oxygenation.

Authors:  Elizabeth K Powell; Daniel J Haase; Allison Lankford; Kimberly Boswell; Emily Esposito; Joseph Hamera; Siamak Dahi; Eric Krause; Gregory Bittle; Kristopher B Deatrick; Bree Ann C Young; Samuel M Galvagno; Ali Tabatabai
Journal:  Perfusion       Date:  2022-04-25       Impact factor: 1.581

8.  Decreased PRESET-Score corresponds with improved survival in COVID-19 veno-venous extracorporeal membrane oxygenation.

Authors:  Elizabeth K Powell; Allison S Lankford; Mira Ghneim; Joseph Rabin; Daniel J Haase; Siamak Dahi; Kristopher B Deatrick; Eric Krause; Gregory Bittle; Samuel M Galvagno; Thomas Scalea; Ali Tabatabai
Journal:  Perfusion       Date:  2022-09-16       Impact factor: 1.581

9.  Pulmonary complications in trauma: Another bellwether for failure to rescue?

Authors:  Dane Scantling; Justin Hatchimonji; Elinore Kaufman; Ruiying Xiong; Wei Yang; Daniel N Holena
Journal:  Surgery       Date:  2020-09-19       Impact factor: 3.982

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.